calendar
229 catalysts · 3,921 phase readout · 2,127 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
229 catalysts · 3,921 phase readout · 2,127 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
AI grant. $209,758. PI: Paul K Drain
AT grant. $601,259. PI: Ashley E. Mason
NS grant. $568,920. PI: Theresa Currier Thomas
CA grant. $496,357. PI: DANIEL J BRAT
AT grant. $170,640. PI: Julia E. Hooker
AI grant. $210,302. PI: William Evan Johnson
DK grant. $231,000. PI: Roger D. Cone
NS grant. $230,562. PI: Thuy Nguyen
ES grant. $117,747. PI: Rebecca Sugrue
Angio Packs (AMS6908E and AMS6908F)
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Vanilla Bourbon Trail Mix
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL